Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Guthrie, 2013, The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer, Crit. Rev. Oncol. Hematol., 88, 218, 10.1016/j.critrevonc.2013.03.010 Templeton, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju124 van Soest, 2015, Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials, Ann. Oncol., 26, 743, 10.1093/annonc/mdu569 Cannon, 2015, Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer, J. Thorac. Oncol., 10, 280, 10.1097/JTO.0000000000000399 Kang, 2014, The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer, Br. J. Cancer, 111, 452, 10.1038/bjc.2014.317 Ferrucci, 2015, Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients, Br. J. Cancer, 112, 1904, 10.1038/bjc.2015.180 Hutchins, 1999, Underrepresentation of patients 65 years of age or older in cancer-treatment trials, N. Engl. J. Med., 341, 2061, 10.1056/NEJM199912303412706 Chavez-MacGregor, 2016, Randomized clinical trials and observational studies: is there a battle?, J. Clin. Oncol., 34, 772, 10.1200/JCO.2015.64.7487 Hershman, 2012, Comparative effectiveness research in oncology methodology: observational data, J. Clin. Oncol., 30, 4215, 10.1200/JCO.2012.41.6701 Giordano, 2015, Comparative effectiveness research in cancer with observational data, Am. Soc. Clin. Oncol. Educ. Book, e330, 10.14694/EdBook_AM.2015.35.e330 Carpenter, 2012, A framework for understanding cancer comparative effectiveness research data needs, J. Clin. Epidemiol., 65, 1150, 10.1016/j.jclinepi.2012.06.005 Zahorec, 2001, Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl. Lek. Listy, 102, 5 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin. Cancer Res., 15, 7412, 10.1158/1078-0432.CCR-09-1624 Chiou, 2015, Pseudoprogression and immune-related response in solid tumors, J. Clin. Oncol., 33, 3541, 10.1200/JCO.2015.61.6870 Korpanty, 2014, Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS, Front. Oncol., 4, 204, 10.3389/fonc.2014.00204 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Di Giacomo, 2015, Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study, Ann. Oncol., 26, 798, 10.1093/annonc/mdu577 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center, J. Clin. Oncol., 33, 3193, 10.1200/JCO.2015.60.8448 Ascierto, 2014, Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort, J. Transl. Med., 12, 116, 10.1186/1479-5876-12-116 Shreders, 2016, Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab, Cancer Immunol. Res., 10.1158/2326-6066.CIR-15-0281 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin. Cancer Res., 10.1158/1078-0432.CCR-16-0127 Bowyer, 2016, Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy, Br. J. Cancer, 114, 1084, 10.1038/bjc.2016.107 Khoja, 2016, Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma, Oncol. Lett., 11, 1581, 10.3892/ol.2015.4069 Jung, 2016, Ipilimumab real-world efficacy and safety in korean melanoma patients from the korean named-patient program cohort, Cancer Res. Treat. Leeneman, 2015, Improved survival with ipilimumab in patients with advanced melanoma in real-world clinical practice: first results of the dutch melanoma treatment registry, Value Health, 18, A440 Ahmad, 2015, Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients, Melanoma Res., 25, 432, 10.1097/CMR.0000000000000185 Tumeh, 2015, Abstract 2857: metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma, Cancer Res., 75, 2857, 10.1158/1538-7445.AM2015-2857 Goldinger, 2016, Abstract 9549: correlation between metastatic site and response to anti-programmed Death-1 (PD-1) agents in melanoma, J. Clin. Oncol., 34, 9549, 10.1200/JCO.2016.34.15_suppl.9549 Riihimaki, 2014, Metastatic sites and survival in lung cancer, Lung Cancer, 86, 78, 10.1016/j.lungcan.2014.07.020 Sperduto, 2012, Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J. Clin. Oncol., 30, 419, 10.1200/JCO.2011.38.0527